Results 81 to 90 of about 2,941,047 (299)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Service Clustering: Building Cohesive Public Service Capacity [PDF]

open access: yes, 2005
The human services support system of Allegheny County, Pennsylvania, incorporates a complex and concentrated network of services for its economically disadvantaged citizens.In 2004, the Allegheny County Department of Human Services (DHS) served 231,400 ...

core  

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Building Agricultural Capacity in Newfoundland and Labrador [PDF]

open access: yes, 2012
Newfoundland and Labrador faces considerable challenges in maintaining a consistent and reliable food supply. The lack of locally produced food has resulted in the province’s dependency on imported foods.
Quinlin, A. James
core  

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns   +10 more
wiley   +1 more source

Building Resident Power and Capacity for Change [PDF]

open access: yes, 2009
An "on the ground" reflection about what it takes for funders to work effective with low-income communities. This report is a set of reflections that began with conversations among fifty people who gathered in Chicago in September of 2008 for Grassroots ...
Kristin Senty, Timothy Saasta
core  

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova   +25 more
wiley   +1 more source

Foreword

open access: yesJàmbá, 2009
The conditions prevailing in the world, where fast growing populations are coupled with rapidly expanding urbanization and a general increase in poverty levels, are greatly aggravating the disaster risks and vulnerabilities of a large part of the world’s
Mmaphaka Tau
doaj   +1 more source

Working Better Together: Building Nonprofit Collaborative Capacity [PDF]

open access: yes, 2013
Collective action is an effective way for nonprofits to increase their impact, but they often lack the key capacities that enable these types of partnerships to thrive.

core  

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy